SCHEMBL6321895

SCHEMBL6321895

NC(=O)c1c(-c2cccs2)noc1NC(=O)COc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
LMNA P02545 3/20 0.54
TSHR P16473 2/20 0.54
TP53 P04637 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPK10 P53779 1/20 0.52
HSD17B10 Q99714 1/20 0.52
POLB P06746 1/20 0.52
THRB P10828 3/20 0.48
HPGD P15428 2/20 0.48
GAA P10253 1/20 0.47
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
USP2 O75604 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318751 0.85 HPGD (0.53) MAPTLMNATP53SMN1; SMN2NPC1
SCHEMBL6316568 0.85 USP2 (0.51) MAPTLMNANPC1RAB9ATHRB
SCHEMBL6319422 0.85 NPC1 (0.55) MAPTLMNATP53SMN1; SMN2NPC1
SCHEMBL6322876 0.83 LMNA (0.55) MAPTLMNATP53SMN1; SMN2NPC1
SCHEMBL6318380 0.81 ALDH1A1 (0.55) MAPTLMNATSHRTP53SMN1; SMN2
SCHEMBL6317632 0.80 ADORA2A (0.53) MAPTTP53SMN1; SMN2RAB9AALDH1A1
SCHEMBL6314638 0.79 ALDH1A1 (0.54) MAPTLMNATP53SMN1; SMN2NPC1
SCHEMBL6317072 0.79 NOTUM (0.55) MAPTLMNATP53SMN1; SMN2NPC1
SCHEMBL6321734 0.79 ALDH1A1 (0.53) MAPTLMNATSHRTP53SMN1; SMN2
SCHEMBL6315136 0.79 ALDH1A1 (0.47) MAPTLMNATSHRTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPT 281/4885LMNA 3334/4885TSHR 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.